Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Efficacy of TKIs in the treatment of HER2+ breast cancer with or without brain mets

Diogo Martins-Branco • 8 Nov 2021
SABCS 2021
Breast Cancer Afatinib Lapatinib Pyrotinib Trastuzumab Tucatinib
HER2CLIMB

Diogo Martins-Branco, MD, MSc, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium, reports on the findings of a systematic review which aimed to assess the clinical outcomes of HER2+ metastatic breast cancer patients with or without brain metastases treated with TKI-containing regimens vs. those treated with non-TKI-containing regimens. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Diogo Martins-Branco

The unmet needs in palliative care for breast cancer
3:12
The unmet needs in palliative care for breast cancer
Diogo Martins-Branco • 7 Dec 2022
The impact of the COVID-19 pandemic on the management of patients with breast cancer
2:45
The impact of the COVID-19 pandemic on the management of patients with breast cancer
Diogo Martins-Branco • 7 Dec 2022
Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancer
6:09
Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancer
Diogo Martins-Branco • 7 Dec 2022
Key clinical trials in breast cancer presented at SABCS 2021
2:56
Key clinical trials in breast cancer presented at SABCS 2021
Diogo Martins-Branco • 8 Dec 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals